Nurix Therapeutics, Inc.
NASDAQNurix Therapeutics reports Thursday with short sellers maintaining a meaningful but slightly retreating position, while options positioning has drifted more cautious and the stock has lost ground through October. Short interest is elevated at 17.2% of the free float, roughly 17.5 million shares. That is the headline bearish signal, though the direction has turned modestly…
NRIX cost to borrow surges to 1.91%, up 282% in one week amid tight share availability and sustained short pressure.
Snapshot as of 13 Oct 2026
Nurix Therapeutics reports Thursday with short sellers maintaining a meaningful but slightly retreating position, while options positioning has drifted more cautious and the stock has lost ground through October. Short…
Nurix Therapeutics enters the week with a sharp contradiction at its core: Needham just raised its price target to $34, yet the stock has shed 18% in the past five days to close at $14.64 — leaving analysts…
Nurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock. Short interest is running at roughly 21.9%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NRIX — free to start on ORTEX.
Sign up for free →Open NRIX on ORTEX